

Overview

Useful For

Detecting drug use involving stimulants, barbiturate, benzodiazepines, cocaine, opioids, tetrahydrocannabinol, alcohol, and nicotine

This test is **not intended for use** in employment-related testing.

Profile Information

Test Id	Reporting Name	Available Separately	Always Performed
LPCM	List Patient's Current Medications	No	Yes
ADULT	Adulterants Survey, U	Yes	Yes
PNRCH	Drug Immunoassay Panel, U	No	Yes
TOPSU	Targeted Opioid Screen, U	Yes, (Order TOSU)	Yes
TABSU	Targeted Benzodiazepine Screen, U	Yes, (Order TBSU)	Yes
TSTIM	Targeted Stimulant Screen, U	Yes, (Order TSPU)	Yes
ETGSR	Ethyl Glucuronide Scrn w/Reflex, U	No	Yes
NICOU	Nicotine and Metabolites, U	Yes	Yes

Reflex Tests

Test Id	Reporting Name	Available Separately	Always Performed
COKEU	Cocaine and metabolite Conf, U	Yes	No
BARBU	Barbiturates Confirmation, U	Yes	No
THCU	Carboxy-THC Confirmation, U	Yes	No
ETGC	Ethyl Glucuronide Confirmation, U	Yes	No

Testing Algorithm

Testing begins with an adulterant survey. If the sample is found to be adulterated, testing will end, and the remaining tests will be canceled.

If the specimen is normal or only diluted, remaining testing will continue.

If immunoassay screen is positive, confirmation testing can be ordered separately. Confirmation with quantification of positives for barbiturates, cocaine and metabolites, tetrahydrocannabinol metabolite, and ethyl glucuronide/ethyl sulfate will be performed at an additional charge.

Special Instructions

- [Clinical Toxicology CPT Code Client Guidance](#)

Method Name

ADULT: Spectrophotometry (SP)

PNRCH: Immunoassay followed by Gas Chromatography Mass Spectrometry (GC-MS) or Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) as needed

TOPSU, TABSU, TSTIM: Liquid Chromatography Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)

ETGSR: Immunoassay followed by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) as needed

NICOU: Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

NY State Available

Yes

Specimen**Specimen Type**

Urine

Ordering Guidance

This test does not screen for drug classes other than those listed in Reference Values.

Specimen Required

Supplies: Urine Container, 60 mL (T313)

Collection Container/Tube: Plastic urine container

Submission Container/Tube: Plastic, 60-mL urine container

Specimen Volume: 30 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Submit 30 mL in 1 plastic bottle.

3. No preservative.

Additional Information:

1. No specimen substitutions.
2. Submitting less than 30 mL may compromise the ability to perform all necessary testing.
3. STAT requests are **not accepted** for this test.

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

- [Renal Diagnostics Test Request](#) (T830)
- [Therapeutics Test Request](#) (T831)
- [Kidney Transplant Test Request](#)

Specimen Minimum Volume

20 mL

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Urine	Refrigerated (preferred)	14 days	
	Frozen	14 days	

Clinical & Interpretive**Clinical Information**

This test uses screening techniques that involve immunoassay testing and high-resolution accurate mass spectrometry screening for drugs by class. All positive immunoassay screening results are confirmed by gas chromatography mass spectrometry (GC-MS) or liquid chromatography tandem mass spectrometry (LC-MS/MS), and quantitated, before a positive result is reported.

The following drugs/drug classes are tested by immunoassay and confirmed by GC-MS:

- Barbiturates
- Cocaine

The following drugs/drug classes are tested by immunoassay and confirmed by LC-MS/MS:

- Carboxy-tetrahydrocannabinol
- Ethyl glucuronide

The targeted opioid, benzodiazepine, and stimulant screen portions are performed using LC-MS/MS high-resolution accurate mass and are completed for all opioids, benzodiazepines, and stimulants.

Opioids are a large class of medications commonly used to relieve acute and chronic pain or help manage opioid abuse and dependence. Medications that fall into this class include buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, oxymorphone, tapentadol, tramadol, and others. Opioids work by binding to the opioid receptors that are found in the brain, spinal cord, gastrointestinal tract, and other organs. Common side effects for opioids include drowsiness, confusion, nausea, constipation, and, in severe cases, respiratory depression. These are dose dependant and vary with tolerance. These medications can also produce physical and psychological dependence and have a high risk for abuse and diversion, which is one of the main reasons many professional practice guidelines recommend compliance testing in patients prescribed these medications.

Opioids are readily absorbed from the gastrointestinal tract, nasal mucosa, lungs, and after subcutaneous or intermuscular injection. Opioids are primarily excreted from the kidney in both free and conjugated forms. This assay does not hydrolyze the urine sample and looks for both parent drugs and metabolites (including glucuronide forms). The detection window for most opioids in urine is approximately 1 to 3 days with longer detection times for some compounds (ie, methadone).

Benzodiazepines represent a large family of medications used to treat a wide range of disorders from anxiety to seizures and are also used in pain management. With a high risk for abuse and diversion, professional practice guidelines recommend compliance monitoring for these medications using urine drug tests. However, traditional benzodiazepine immunoassays suffer from a lack of cross-reactivity with all the benzodiazepines, so many compliant patients taking either clonazepam (Klonopin) or lorazepam (Ativan) may screen negative by immunoassay but are positive when confirmatory testing is done. The new targeted benzodiazepine screening test provides a more sensitive and specific test to check for compliance to all the commonly prescribed benzodiazepines and looks for both parent drugs and metabolites in the urine.

Stimulants are sympathomimetic amines that stimulate the central nervous system activity and, in part, suppress the appetite. Amphetamine and methamphetamine are also prescription drugs used in the treatment of narcolepsy and attention-deficit disorder/attention-deficit hyperactivity disorder (ADHD). Methylphenidate is another stimulant used to treat ADHD. Phentermine is indicated for the management of obesity. All other amphetamines (eg, methylenedioxymethamphetamine: MDMA) are Drug Enforcement Administration-scheduled Class I compounds. Due to their stimulant effects, the drugs are commonly sold illicitly and abused. Physiological symptoms associated with very high amounts of ingested amphetamine or methamphetamine include elevated blood pressure, dilated pupils, hyperthermia, convulsions, and acute amphetamine psychosis.

Ethyl glucuronide is a direct metabolite of ethanol that is formed by enzymatic conjugation of ethanol with glucuronic acid. Alcohol in urine is normally detected for only a few hours, whereas ethyl glucuronide can be detected in the urine for 1 to 3 days. This procedure uses immunoassay reagents that are designed to produce a negative result when no drugs are present in a natural (eg, unadulterated) specimen of urine; the assay is designed to have a high true-negative rate. Like all immunoassays, it can have a false-positive rate due to cross-reactivity with natural chemicals and drugs

other than those they were designed to detect. The immunoassay also has a false-negative rate to the antibody's ability to cross-react with different drugs in the class for which it is being screened.

Tobacco use is the leading cause of death in the United States. Nicotine, coadministered in tobacco products such as cigarettes, pipe, cigar, or chew is an addicting substance that causes individuals to continue use of tobacco despite concerted efforts to quit. Nicotine stimulates dopamine release and increases dopamine concentration in the nucleus accumbens, a mechanism that is thought to be the basis for addiction for drugs of abuse.

Nicotine is rapidly metabolized in the liver to cotinine, exhibiting an elimination half-life of 2 hours. Cotinine exhibits an apparent elimination half-life of approximately 15 to 19 hours. Patients using tobacco products excrete nicotine in urine in the concentration range of 1000 to 5000 ng/mL. Cotinine accumulates in urine in proportion to dose and hepatic metabolism, which is genetically determined; most tobacco users excrete cotinine in the range of 1000 to 8000 ng/mL. Urine concentrations of nicotine and metabolites in these ranges indicate the subject is using tobacco or is receiving high-dose nicotine patch therapy.

In addition to nicotine and metabolites, tobacco products also contain other alkaloids that can serve as unique markers of tobacco use. Two such markers are anabasine and nornicotine. Anabasine is present in tobacco products but not nicotine replacement therapies. Nornicotine is present as an alkaloid in tobacco products and as a metabolite of nicotine. The presence of anabasine greater than 10 ng/mL or nornicotine greater than 30 ng/mL in urine indicates current tobacco use irrespective of whether the subject is on nicotine replacement therapy. The presence of nornicotine without anabasine is consistent with use of nicotine replacement products. Heavy tobacco users who abstain from tobacco for 2 weeks exhibit urine nicotine values below 30 ng/mL, cotinine values below 50 ng/mL, anabasine levels below 2 ng/mL, and nornicotine levels below 2 ng/mL.

Passive exposure to tobacco smoke can cause accumulation of nicotine metabolites in nontobacco users. Urine cotinine has been observed to accumulate up to 20 ng/mL from passive exposure. Neither anabasine nor nornicotine accumulates from passive exposure.

Tobacco users engaged in programs to abstain from tobacco require support in the form of counseling, pharmacotherapy, and continuous encouragement. Occasionally, counselors may elect to monitor abstinence by biochemical measurement of nicotine and metabolites in a random urine specimen to verify abstinence. If results of biologic testing indicate the patient is actively using a tobacco product during therapy, additional counseling or intervention may be appropriate.

Quantification of urine nicotine and metabolites while a patient is actively using a tobacco product is useful to define the concentrations that a patient achieves through self-administration of tobacco. Nicotine replacement dose can then be tailored to achieve the same concentrations early in treatment to assure adequate nicotine replacement so the patient may avoid the strong craving they may experience early in the withdrawal phase. This can be confirmed by measurement of urine nicotine and metabolite concentrations at steady state (2-3 days after replacement therapy is started). Once the patient is stabilized on the dose necessary to achieve complete replacement and responding well to therapy, the replacement dose can be slowly tapered to achieve complete withdrawal.

This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.

Reference Values

ADULTERANT SURVEY:

Cutoff concentrations

Oxidants: 200 mg/L

Nitrites: 500 mg/L

DRUG IMMUNOASSAY PANEL:

Negative

Screening cutoff concentrations:

Barbiturates: 200 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

TARGETED OPIOID SCREEN:

Not detected (Positive results are reported with qualitative "Present" results)

Cutoff concentrations:

Codeine: 25 ng/mL

Codeine-6-beta-glucuronide: 100 ng/mL

Morphine: 25 ng/mL

Morphine-6-beta-glucuronide: 100 ng/mL

6-monoacetylmorphine: 25 ng/mL

Hydrocodone: 25 ng/mL

Norhydrocodone: 25 ng/mL

Dihydrocodeine: 25 ng/mL

Hydromorphone: 25 ng/mL

Hydromorphone-3-beta-glucuronide: 100 ng/mL

Oxycodone: 25 ng/mL

Noroxycodone: 25 ng/mL

Oxymorphone: 25 ng/mL

Oxymorphone-3-beta-glucuronide: 100 ng/mL

Noroxymorphone: 25 ng/mL

Fentanyl: 2 ng/mL

Norfentanyl: 2 ng/mL

Meperidine: 25 ng/mL

Normeperidine: 25 ng/mL

Naloxone: 25 ng/mL

Naloxone-3-beta-glucuronide: 100 ng/mL
Methadone: 25 ng/mL
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP): 25 ng/mL
Propoxyphene: 25 ng/mL
Norpropoxyphene: 25 ng/mL
Tramadol: 25 ng/mL
O-desmethyltramadol: 25 ng/mL
Tapentadol: 25 ng/mL
N-desmethyltapentadol: 50 ng/mL
Tapentadol-beta-glucuronide: 100 ng/mL
Buprenorphine: 5 ng/mL
Norbuprenorphine: 5 ng/mL
Norbuprenorphine glucuronide: 20 ng/mL

TARGETED BENZODIAZEPINE SCREEN:

Not detected (Positive results are reported with qualitative "Present" results)

Cutoff concentrations:

Alprazolam: 10 ng/mL

Alpha-hydroxyalprazolam: 10 ng/mL

Alpha-hydroxyalprazolam glucuronide: 50 ng/mL

Chlordiazepoxide: 10 ng/mL

Clobazam: 10 ng/mL

N-desmethylclobazam: 200 ng/mL

Clonazepam: 10 ng/mL

7-Aminoclonazepam: 10 ng/mL

Diazepam: 10 ng/mL

Nordiazepam: 10 ng/mL

Flunitrazepam: 10 ng/mL

7-Aminoflunitrazepam: 10 ng/mL

Flurazepam: 10 ng/mL

2-Hydroxy ethyl flurazepam: 10 ng/mL

Lorazepam: 10 ng/mL

Lorazepam glucuronide: 50 ng/mL

Midazolam: 10 ng/mL

Alpha-hydroxymidazolam: 10 ng/mL

Oxazepam: 10 ng/mL

Oxazepam glucuronide: 50 ng/mL

Prazepam: 10 ng/mL

Temazepam: 10 ng/mL

Temazepam glucuronide: 50 ng/mL

Triazolam: 10 ng/mL

Alpha-hydroxytriazolam: 10 ng/mL
Zolpidem: 10 ng/mL
Zolpidem phenyl-4-carboxylic acid: 10 ng/mL

TARGETED STIMULANT SCREEN:

Not detected (Positive results are reported with qualitative "Present" results)

Cutoff concentrations:

Methamphetamine: 100 ng/mL
Amphetamine: 100 ng/mL
3,4-Methylenedioxymethamphetamine (MDMA): 100 ng/mL
3,4-Methylenedioxymethamphetamine (MDEA): 100 ng/mL
3,4-Methylenedioxymethamphetamine (MDA): 100 ng/mL
Ephedrine: 100 ng/mL
Pseudoephedrine: 100 ng/mL
Phentermine: 100 ng/mL
Phencyclidine (PCP): 20 ng/mL
Methylphenidate: 20 ng/mL
Ritalinic acid: 100 ng/mL

ETHYL GLUCURONIDE SCREEN:

Negative

Screening cutoff concentration:

Ethyl glucuronide: 500 ng/mL

NICOTINE AND METABOLITES:

Non-tobacco user with no passive exposure:
Nicotine: <5.0 ng/mL
Cotinine: <5.0 ng/mL
Anabasine: <2.0 ng/mL
Nornicotine: <2.0 ng/mL

Interpretation

A positive result derived by this testing indicates that the patient has used one of the drugs detected by these techniques in the recent past.

For information about drug testing, including estimated detection times and [Result Interpretations](#), see [Addiction rehabilitation monitoring](#) on MayoClinicLabs.com.

Cautions

Care should be taken when interpreting results since there are many factors (eg, fluid intake and other biologic factors)

that may influence a urine test result. It is possible that substances other than those investigated in the specificity study may interfere with the test and cause false-positive or negative results.

Knowledge of time elapsed between last dose and specimen collection is important for interpretation of test results.

Clinical Reference

1. Physicians' Desk Reference; 60th ed. Medical Economics Company, 2006
2. Bruntman LL, ed. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill Book Company; 2006
3. Langman LJ, Bechtel LK, Holstege CP. Clinical toxicology. In: Rifai N, Chiu RWK, Young I, Burnham CAD, Wittwer CT, eds. Tietz Textbook of Laboratory Medicine. 7th ed. Elsevier; 2023:chap 43
4. Gutstein HB, Akil H. Opioid analgesics. In. Brunton LL, Lazo JS, Parker KL, eds: Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill Companies; 2006
5. Rovine T, Ferrero CL, American Pain Society: Chronic Pain in America: Roadblocks to Relief. Roper Starch Worldwide, Inc; 1999. Updated 2001. Accessed December 13, 2024. Available at <http://accurateclinic.com/wp-content/uploads/2016/04/Chronic-Pain-In-America-Roadblocks-To-Relief-1999.pdf>
6. Magnani B, Kwong T. Urine drug testing for pain management. Clin Lab Med. 2012;32(32):379-390
7. Jannetto PJ, Bratanow NC, Clark WA, et al. Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline-using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2(4):489-526
8. McMillin GA, Marin SJ, Johnson-Davis KL, Lawlor BG, Strathmann FG. A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. Am J Clin Pathol. 2015;143(2):234-240
9. Cone EJ, Caplan YH, Black DL, Robert T, Moser F. Urine drug testing of chronic pain patients: licit and illicit drug patterns. J Anal Toxicol. 2008;32(8):530-543
10. American Society of Addiction Medicine Consensus Statement. Appropriate Use of Drug Testing in Clinical Addiction Medicine. American Society of Addiction Medicine; 2017. Accessed December 13, 2024. Available at www.asam.org/docs/default-source/quality-science/the-asam-appropriate-use-of-drug-testing-in-clinical-addiction-medicine-full-document.pdf

Performance

Method Description

Adulterant:

All results are measured using spectrophotometry at wavelengths specified by the reagent manufacturer. The use of a refractometer may also be used in the specific gravity measurement.(Package inserts: Specimen Validity Test Creatinine. Roche Diagnostics; V3.0, 08/2015; Specimen Validity Test Nitrite. Roche Diagnostics; V3.0, 08/2018, Specimen Validity Test Oxidant. Roche Diagnostics; V 3.0, 08/2018; Specimen Validity Test pH Roche Diagnostics; V3.0, 02/2019, Specimen Validity Test Specific Gravity. Roche Diagnostics; V4.0, 08/2022)

Drug Panel:

The barbiturate, cocaine metabolite, and tetrahydrocannabinol metabolite assays are based on the kinetic interaction of microparticles in a solution as measured by changes in light transmission. In the absence of sample drug, soluble drug conjugates bind to antibody-bound microparticles, causing the formation of particle aggregates. As the aggregation reaction proceeds in the absence of sample drug, the absorbance increases. When a urine sample contains the drug in question, this drug competes with the drug derivative conjugate for microparticle-bound antibody. Antibody bound to sample drug is no longer available to promote particle aggregation, and subsequent particle lattice formation is inhibited. The presence of sample drug diminishes the increasing absorbance in proportion to the concentration of drug in the sample. Sample drug content is determined relative to the value obtained for a known cutoff concentration of drug.(Package inserts: BARB. Roche Diagnostics; V 13.0, 09/2021; THC2. Roche Diagnostics; V 13.0, 03/2022; COC2. Roche Diagnostics; V 9.0, 03/2019)

Targeted Screening Panels for opioids, benzodiazepines, and stimulants:

The urine sample is diluted with internal standard and clinical laboratory reagent water and then analyzed by liquid chromatography tandem mass spectrometry using a high resolution-accurate mass orbitrap detector.(Unpublished Mayo method)

Ethyl Glucuronide Screen:

This assay is a homogeneous, semiquantitative enzyme immunoassay. The assay is based on competition between free drug in the urine sample and a drug labeled with the enzyme glucose-6-phosphate dehydrogenase for a fixed amount of specific antibody binding sites. Active enzyme converts nicotinamide adenine dinucleotide (NAD[+]) to NADH, which results in an absorbance change that can be measured spectrophotometrically at 340 nm.(Package insert: DRI Ethyl Glucuronide Assay. Microgenics Corporation; 09/2015)

Nicotine and Metabolites:

Nicotine and metabolites are extracted from urine by solid-phase extraction techniques. The extract eluate is quantified by high-performance liquid chromatography tandem mass spectrometry.(Moyer TP, Charlson JR, Enger RJ, et al. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. *Clin Chem.* 2002;48[9]:1460-1471; Oh J, Park MS, Chun MR, et al. A simple and high-throughput LC-MS/MS method for simultaneous measurement of nicotine, cotinine, 3-OH cotinine, nornicotine, and anabasine in urine and its application in the general Korean population. *J Anal Toxicol.* 2022;46(1):25-36. doi:10.1093/jat/bkaa177)

PDF Report

No

Day(s) Performed

Monday through Saturday

Report Available

2 to 5 days

Specimen Retention Time

2 weeks**Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Superior Drive

Fees & Codes**Fees**

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

80307

G0482

G0483 (if appropriate for select payers)

80347 (if appropriate for select payers)

80364 (if appropriate for select payers)

80326 (if appropriate for select payers)

80323 (if appropriate for select payers)

[Clinical Toxicology CPT Code Client Guidance](#)**LOINC® Information**

Test ID	Test Order Name	Order LOINC® Value
ADMPU	Addiction Med Profile,22,HRMS/IA, U	12286-1

Result ID	Test Result Name	Result LOINC® Value
20606	Creatinine, U	2161-8
22312	Specific Gravity	In Process
23509	pH	2756-5
23511	Oxidants	58714-7
23510	Nitrites	32710-6
30914	Comment	48767-8
82510	Nicotine	3854-7
21321	Cotinine	10366-3

21324	Nornicotine	33917-6
21323	Anabasine	33915-0
42323	Codeine	19411-8
42324	Codeine-6-beta-glucuronide	89310-7
42325	Morphine	19597-4
42326	Morphine-6-beta-glucuronide	89308-1
42327	6-monoacetylmorphine	19321-9
42328	Hydrocodone	19482-9
42329	Norhydrocodone	89304-0
42330	Dihydrocodeine	19446-4
42331	Hydromorphone	19486-0
42332	Hydromorphone-3-beta-glucuronide	89309-9
42333	Oxycodone	19642-8
42334	Noroxycodone	89303-2
42335	Oxymorphone	19646-9
42336	Oxymorphone-3-beta-glucuronide	89301-6
42337	Noroxymorphone	89302-4
42338	Fentanyl	59673-4
42339	Norfentanyl	43199-9
42340	Meperidine	19532-1
42341	Normeperidine	27920-8
42342	Naloxone	42618-9
42343	Naloxone-3-beta-glucuronide	89307-3
42344	Methadone	19550-3
42345	EDDP	93495-0
42346	Propoxyphene	19429-0
42347	Norpropoxyphene	19632-9
42348	Tramadol	19710-3
42349	O-desmethyltramadol	86453-8
42350	Tapentadol	72485-6
42351	N-desmethyltapentadol	89306-5
42352	Tapentadol-beta-glucuronide	89300-8
42353	Buprenorphine	93494-3
42354	Norbuprenorphine	82371-6
42355	Norbuprenorphine glucuronide	89305-7
65059	Opioid Interpretation	69050-3
2574	Barbiturates	70155-7
21652	Cocaine	19359-9
2664	Tetrahydrocannabinol	19415-9
604871	Alprazolam	94116-1

604867	Alpha-Hydroxyalprazolam	19325-0
604891	Alpha-Hydroxyalprazolam Glucuronide	94115-3
604872	Chlordiazepoxide	19385-4
604889	Clobazam	94114-6
604890	N-Desmethylclobazam	94113-8
604873	Clonazepam	19399-5
604267	7-aminoclonazepam	94112-0
604874	Diazepam	19443-1
604880	Nordiazepam	19624-6
604875	Flunitrazepam	19466-2
604866	7-aminoflunitrazepam	94111-2
604876	Flurazepam	19474-6
604868	2-Hydroxy Ethyl Flurazepam	94110-4
604877	Lorazepam	19520-6
604878	Lorazepam Glucuronide	94109-6
604879	Midazolam	19585-9
604869	Alpha-Hydroxy Midazolam	94108-8
604881	Oxazepam	19638-6
604882	Oxazepam Glucuronide	94107-0
604883	Prazepam	19678-2
604884	Temazepam	19698-0
604885	Temazepam Glucuronide	94106-2
604886	Triazolam	19714-5
604870	Alpha-Hydroxy Triazolam	94105-4
604887	Zolpidem	94104-7
604888	Zolpidem Phenyl-4-Carboxylic acid	94103-9
604949	Benzodiazepine Interpretation	69050-3
LPCM	List Patient's Current Medications	66423-5
610273	Methamphetamine	19554-5
610274	Amphetamine	19343-3
610275	3,4-methylenedioxymethamphetamine (MDMA)	19568-5
610276	3,4-methylenedioxy-N-ethylamphetamine (MDEA)	59844-1
610277	3,4-methylenedioxymphetamine (MDA)	19565-1
610278	Ephedrine	99108-3
610279	Pseudoephedrine	99109-1
610280	Phentermine	19674-1

Test Definition: ADMPU

Addiction Medicine Profile with Reflex, 22
Drug Classes, High Resolution Mass
Spectrometry and Immunoassay Screen,
Random, Urine

610281	Phencyclidine (PCP)	19659-2
610282	Methylphenidate	19577-6
610283	Ritalinic acid	99110-9
610284	Stimulant Interpretation	54247-2
616033	Ethyl Glucuronide Screen, U	58375-7